Physician profile
Saad Munib Ahmed Khan
NPI 1083767024
$262,044.17
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $55K · 2021: $63K · 2022: $75K · 2023: $42K · 2024: $7,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Consulting Fee: $11K · Food and Beverage: $1,044 · Travel and Lodging: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,450.00 |
| Consulting Fee | $11,117.50 |
| Food and Beverage | $1,043.67 |
| Travel and Lodging | $1,011.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $231,007.50 | 2019-2023 | Foundationone Cdx |
| Eisai INC. | $12,178.39 | 2019-2023 | |
| Coherus Oncology, INC. | $5,892.99 | 2022-2024 | |
| Genmab U.S., INC. | $5,688.84 | 2024 | Tivdak |
| Genentech, INC. | $4,431.57 | 2019 | |
| Merck Kgaa | $1,725.00 | 2022 | |
| Incyte Corporation | $132.50 | 2019-2024 | Jakafi |
| Astellas Pharma US INC | $123.80 | 2023-2024 | Xtandi, Padcev |
| E.R. Squibb & Sons, L.L.C. | $118.13 | 2022 | |
| Abbvie INC. | $108.34 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $94.30 | 2019-2021 | |
| Amgen INC. | $75.98 | 2019-2023 | Lumakras |
| Janssen Biotech, INC. | $64.00 | 2020-2024 | Erleada |
| Lilly USA, LLC | $57.38 | 2019-2020 | |
| Eli Lilly and Company | $51.86 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $45.52 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $45.21 | 2024 | Libtayo |
| Mylan Institutional INC. | $43.59 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $30.09 | 2019 | |
| Daiichi Sankyo INC. | $29.25 | 2024 | Enhertu |
| Genentech USA, INC. | $26.17 | 2023 | Polivy, Lunsumio |
| Novartis Pharmaceuticals Corporation | $21.50 | 2020 | |
| Seagen INC. | $18.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.90 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $15.37 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Munib Ahmed Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.